These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25017515)

  • 21. Drugging MYCN through an allosteric transition in Aurora kinase A.
    Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
    Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined inhibition of Aurora-A and ATR kinase results in regression of
    Roeschert I; Poon E; Henssen AG; Garcia HD; Gatti M; Giansanti C; Jamin Y; Ade CP; Gallant P; Schülein-Völk C; Beli P; Richards M; Rosenfeldt M; Altmeyer M; Anderson J; Eggert A; Dobbelstein M; Bayliss R; Chesler L; Büchel G; Eilers M
    Nat Cancer; 2021 Mar; 2(3):312-326. PubMed ID: 33768209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
    J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
    Wang SS; Hsiao R; Limpar MM; Lomahan S; Tran TA; Maloney NJ; Ikegaki N; Tang XX
    Int J Mol Med; 2014 Jan; 33(1):35-42. PubMed ID: 24190252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
    Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystal structure of a covalently linked Aurora-A-MYCN complex.
    Diebold M; Schönemann L; Eilers M; Sotriffer C; Schindelin H
    Acta Crystallogr D Struct Biol; 2023 Jan; 79(Pt 1):1-9. PubMed ID: 36601802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.
    Ding L; Ren C; Yang L; Wu Z; Li F; Jiang D; Zhu Y; Lu J
    Drug Des Devel Ther; 2021; 15():1797-1810. PubMed ID: 33958857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.
    Ikegaki N; Hicks SL; Regan PL; Jacobs J; Jumbo AS; Leonhardt P; Rappaport EF; Tang XX
    Int J Oncol; 2014 Jan; 44(1):35-43. PubMed ID: 24173829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
    Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
    PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
    To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
    Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.
    Yang D; Liu H; Goga A; Kim S; Yuneva M; Bishop JM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13836-41. PubMed ID: 20643922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.